HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 22 October 2018

September’s CEAs, systematic reviews and epidemiological models in LMICs

To help us keep on top of current research in low and middle-income countries, we are running a monthly search of research that is aligned to our core research interests.  It's a simple search strategy, with those published last month that are most aligned to our interests listed below.  The full list of articles is kept in our "Searches archive" in the right-hand column.
  • Balhara KS, Bustamante ND, Selvam A, Winders WT, Coker A, Trehan I, et al. Bystander Assistance for Trauma Victims in Low- and Middle-Income Countries: A Systematic Review of Prevalence and Training Interventions. Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors. 2018:1-22.
  • Bessell PR, Lumbala C, Lutumba P, Baloji S, Bieler S, Ndung'u JM. Cost-effectiveness of using a rapid diagnostic test to screen for human African trypanosomiasis in the Democratic Republic of the Congo. PloS one. 2018;13(9):e0204335.
  • Chen P, Ma A, Liu Q. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China. Clinical drug investigation. 2018.
  • Cui S, Tobe RG, Mo X, Liu X, Xu L, Li S. Correction to: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. BMC infectious diseases. 2018;18(1):487.
  • Dol J, Campbell-Yeo M, Tomblin Murphy G, Aston M, McMillan D, Richardson B. Impact of mobile health interventions during the perinatal period for mothers in low- and middle-income countries: a systematic review protocol. JBI database of systematic reviews and implementation reports. 2018.
  • Ma X, Wang Q, Ong JJ, Fairley CK, Su S, Peng P, et al. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis. Sexually transmitted infections. 2018;94(6):434-42.
  • Men P, Yi Z, Li C, Qu S, Xiong T, Yu X, et al. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. BMC psychiatry. 2018;18(1):286.

Thursday, 18 October 2018

Novartis and Bayer appeal High Court Avastin ruling

From Pharmafile:

Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning groups (CCGs) decision to use a cheaper alternative to the two company’s treatments for wet AMD.
While courts backed the NHS commissioning bodies' decision to use Avastin to treat the leading cause of age-related vision loss in the UK, wet AMD, in September of this year; Novartis and Bayer, who produce more expensive alternatives, Lucentis and Eylea, are seeking permission to appeal the British court’s ruling.
The ruling allowed NHS hospitals to use Avastin, a drug approved for the treatment of cancer, which is 30 times cheaper than Novartis and Bayer’s treatments, instead of Novartis and Bayer’s medications.
However the multinational drugmakers are seeking to appeal the decision. A spokesperson for Novartis said: “Today, people living with wet AMD are now being asked to compromise on the assured quality and safety of their treatment, purely on the basis of cost. This is inappropriate and unnecessary. In the future, on the basis of this judgment, it may be people living with cancer, diabetes, or any other long-term condition being asked to compromise on the quality and safety of their treatments.”
An unofficial spokesperson for HEDS said: “Today, people being treated by the NHS are being asked to have their treatments cut and health compromised, purely on the basis of Novartis and Bayer’s desire to maintain profits.  This is inappropriate and unnecessary. In the future, on the basis of this judgment, people living with cancer, diabetes, or any other long-term condition will have the quality and safety of their treatments maintained.”

Wednesday, 17 October 2018

September’s CEAs.....

We’ve completed our quick search for CEA’s published last month.   In the right-hand column of this blog is a CEA Archive of all records.  Below are those in our areas of interest.
  • Heath K. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C. ClinicoEconomics and outcomes research : CEOR. 2018;10:539-50.
  • Hersh AR, Megli CJ, Caughey AB. Repeat Screening for Syphilis in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2018;132(3):699-707.
  • Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018.

Tuesday, 16 October 2018

New HEDS DSU Report - Comparing the EQ-5D-3L and 5L versions.

The Decision Support Unit at ScHARR have published a new report. 
Comparing the EQ-5D-3L and 5L versions. What are the implications for model-based cost effectiveness estimates? 
HEDS Authors:
Becky Pennington
Monica Hernandez-Alava
Stephen Pudney
Allan Wailoo

You can download the report here


Monday, 15 October 2018

ReQoL in Practice Event - November 29th - Sheffield

Register now for ReQoL in Practice event

Date: 29/11/18
Venue: The Showroom Workstation, Sheffield
Cost: Free

The first national ReQoL in Practice event will be held in Sheffield on 29/11/18. The event is an opportunity for clinicians, peer support workers, managers, outcome leads, commissioners and service users to come together to create a community of practice, sharing learning and knowledge about implementing ReQoL and the use of ReQoL in clinical practice and quality improvement. 

Event highlights include an address by Professor Tim Kendall, NHS England's National Clinical Director for Mental health, and structured opportunities for delegates to share learning across different trusts and organisations.

The target audience is practitioners, managers, outcome leads, IT leads, and commissioners. We would welcome Service Users to attend the event and can offer a limited number of travel bursaries. 
You can find out more here http://clahrc-yh.nihr.ac.uk/our-
themes/health-economics-and-outcome-measurement/6-heom-events

Details about the event including how to register can be seen here
https://www.eventbrite.com/e/reqol-in-practice-event-2018-by-the-university-of-sheffield-
tickets-50849297618

This event is hosted jointly by the University of Sheffield and CLAHRC-YH
If you have any queries then please direct them to Amanda Lane, email: clahrc-
heom@sheffield.ac.uk

Thursday, 11 October 2018

University of Sheffield to provide decision support unit for NICE (DSU)

The University of Sheffield are to provide decision support unit for NICE for a further two years from March 2019, after a competitive tender process.

Image of NICE DSU Website
NICE DSU Website
Subscribe to read our reports and publications first by signing up today at nicedsu.org.uk

Wednesday, 10 October 2018

EEPRU Update

Image of EEPRU Logo
EEPRU
The University of York and University of Sheffield are to jointly provide a five-year NIHR Policy Research Unit in "Economic Methods of Evaluation in Health and Social Care Interventions" starting January 2019.


Be one of the first to read our reports and publications by signing up today at   


Monday, 8 October 2018

Issue 6 of the CLAHRC YH HEOM Newsletter is now out

Image of HEOM Newsletter
HEOM Newsletter
Issue 6 of the CLAHRC YH HEOM Newsletter is now out.  In this issue you can read about:
  • Dr Aimée Fox from the University of York, provides an overview of recent work into evaluating a model of care referred to as ‘Core 24’, including the findings.  
  • Dr Matt Franklin explains the Sheffield Test Bed: Falls-prevention care pathway, the modelling-based approach chosen to perform an exploratory economic evaluation of a falls-prevention care pathway and the three key aspects it incorporated.  
  • Health Economists from the University of Sheffield (ScHARR) and University of York (CHE) discuss the paper they are developing titled "An educational review about using cost data for the purpose of cost-effectiveness analysis".  
  • Dr Lizzie Taylor Buck who invites you to the first national ReQoL in Practice event being held in Sheffield on the 29th November 2018. A link to register for the event can be found here
If you have not received a copy of issues 1, 2, 3, 4 or 5 of our newsletter, please visit the CLAHRC YH HEOM Theme webpages to download your copy at http://tinyurl.com/y9rou6c3

Wednesday, 3 October 2018

Five fully-funded PhD studentships available at ScHARR


Image of Wellcome Trust logo
Wellcome Trust
Five fully-funded PhD studentships available in the Wellcome Trust Doctoral Training Centre for Public Health, Health Economics and Decision Science.
Generously funded by the Wellcome Trust and University of Sheffield, our four-year PhD Programme in Public Health Decision Science provides unique interdisciplinary training to equip graduates to be public health leaders and decision scientists of the future.

We award 5 studentships per year (three funded by the Wellcome Trust and two by the University of Sheffield), two of which can cover overseas fees. Each studentship provides a stipend of £19,919 pa increasing to £23,997 pa over the 4 years, tuition fees for 4 years, worth £5,052 pa for Home/EU students or £18,750 pa for international students and research costs.

The closing date for receipt of all required documentation and references is 5 December 2016.

Tuesday, 2 October 2018

Cochrane Collaboration Issue 9, 2018…

….is complete.  The website lists reviews and protocols.  Of note are……
  • Methods for blood loss estimation after vaginal birth
  • Antigen‐specific active immunotherapy for ovarian cancer
  • Dornase alfa for cystic fibrosis
  • Factors that influence women’s engagement with breastfeeding support: a qualitative evidence synthesis